BioWorld Science

April 18, 2012

View Archived Issues

Taisho Pharmaceutical announces new GlyT1 inhibitors

Read More

New Exp1 inhibitors show promise in a number of in vitro and in vivo cancer studies

Read More

Morphotek evaluates MORAb-004 in new phase II trial

Read More

BioAlliance plans phase II Clonidine Lauriad study expansion

Read More

FDA requests more information for HyQ BLA

Read More

PRINT nanofabrication allows precision synthesis of therapeutic particles

Read More

Merck & Co. selects lead from new series of phosphodiesterase 10A inhibitors

Read More

Sanofi presents novel oncolytic drug candidate

Read More

Preclinical results demonstrate significant early antitumor efficacy of new immunotherapy

Read More

Johnson & Johnson reviews progress of first quarter 2012

Read More

DFH Pharma and NIH collaborate on development of HIV drugs

Read More

Abbott in-licenses Stanford University biomarkers for prostate cancer

Read More

Dyax and Eclipse Therapeutics enter licensing agreement

Read More

Highly potent and selective EZH2 inhibitors discovered by GSK

Read More

Depomed plans NDA filing for Serada

Read More

Novel ERK inhibitors designed

Read More

Novel PI3Kalpha/mTOR inhibitors developed at Hutchison MediPharma

Read More

Exelixis scientists discover new JAK1 inhibitors

Read More

New lysophospholipid S1P1 receptor agonists patented

Read More

Treatment begins in phase II IMO-3100 trial

Read More

Melanoma trial of SCIB-1 clear to advance to phase II

Read More

Intellect Neurosciences collaborates with leading Alzheimer's research group

Read More

AMRI enters into development and manufacturing deal

Read More

ImmunoGen reports advances in its anticancer drug pipeline

Read More

GE Healthcare enters Alzheimer's disease collaboration

Read More

Confirmatory data support efficacy of Phytopharm ALS candidate drug

Read More